Home
Issues
About
Editorial Board
Instructions to Authors
Editorial Policies
3/2012 vol. 25
Stats
Get citation
REVIEW
Medication for the treatment of lung cancer: Emphasis on aerosolized chemotherapy
,
 
,
 
 
 
 
More details
Hide details
1
Master’s Degree Student, Laboratory of Biopharmaceutics and Pharmacokinetics, Faculty of Pharmacy, National and Kapodistrian University of Athens, Greece
2
Professor of Biopharmaceutics and Pharmacokinetics, Laboratory of Biopharmaceutics and Pharmacokinetics, Faculty of Pharmacy, National and Kapodistrian University of Athens, Athens, Greece
CORRESPONDING AUTHOR
Panos Macheras   

School of Pharmacy, National and Kapodistrian University of Athens, Panepistimiopolis, 157 71 Athens
 
Pneumon 2012;25(3):298–304
 
Article (PDF)
References (62)
 
KEYWORDS
lung cancer
 aerosolized chemotherapy
 dry powder aerosols
 
ABSTRACT
Lung cancer is fast becoming the leading cause of death from malignant disease, not only in men but also in women. The prevention of lung cancer entails abstaining from cigarette smoking, which is the main risk factor. The low survival rate of patients suffering from lung cancer, along with the adverse side-effects of chemotherapy in current use, creates a fundamental need for the development of new therapeutic agents and new methods of administration. This review focuses on the anatomical and clinical pathology of lung cancer and the medications currently prescribed in clinical practice for its treatment. Emphasis is given to the administration of anticancer drugs using dry powder inhalers. Aerosolized chemotherapy is described and its advantages and disadvantages are delineated. Research programmes and clinical studies aiming at the formulation of the known anticancer drugs in dry powder aerosols are highlighted.
 
REFERENCES (62)
1.
Geddes DM. The natural history of lung cancer. Br J Dish Chest, 1979; 73(1):1-17.
Google Scholar
 
 
2.
Aaronchick JM. Lung cancer: epidemiology and risk factors. Semin Roentgenol, 1990; 25:5.
Google Scholar
 
 
3.
Stein JH, Hatton JJ, Kohler P. Stein Pathology. Ιατρικές εκδόσεις Πασχαλίδης, 2003.
Google Scholar
 
 
4.
Velsemes M. Καρκίνος του Πνεύμονα. Παθολογία ΔΕΠ, 2002; 274-280.
Google Scholar
 
 
5.
Iannuzzi MC, Miller Y. The genetic predisposition to lung cancer. Semin Res Med 7, 1986; 327.
Google Scholar
 
 
6.
Spiro SG. Carcinoma of the lung. Eur Resp Mon, 1995; 1(1): 1–394.
Google Scholar
 
 
7.
Lyubsky S, Jacobson MJ. Lung Cancer: Making the diagnosis. Chest, 1991; 100:511.
Google Scholar
 
 
8.
Patakas D. “Επίτομη Πνευμονολογία” Κεφ. 17 - Ιστοπαθολογία, σελ. 301-302.
Google Scholar
 
 
10.
Kotoulas XS. Τι πρέπει να γνωρίζουμε για τον καρκίνο του πνεύμονα. Στρατιωτική Επιθεώρηση, Μαρ-Απρ 2003.
Google Scholar
 
 
11.
American Cancer Society, http://www.cancer.org/Cancer/L....
Google Scholar
 
 
12.
Mouratidou D, Andreadis X, Papazisis K, et al. Βασικά Χημειοθεραπευτικά Σχήματα. Αντικαρκινικό Νοσοκομείο Θεσ/νίκης «Θεαγένειο», Ιούλιος 2009.
Google Scholar
 
 
13.
Bang Y, Kwak EL, Shaw T, et al. Clinical activity of the oral ALK inhibitor PF-02341066 in ALK-positive patients with non-small cell lung cancer (NSCLC). J Clin Oncol, (suppl; abstr 3), 2010; 28:7s.
Google Scholar
 
 
15.
Arteaga CL, Khuri F, Krystal G, et al. Overview of rationale and clinical trials with signal transduction inhibitors in lung cancer. Sem Oncol 2002; 29: 15-26.
Google Scholar
 
 
16.
Herbst RS, Langer CJ. Epidermal growth factor as a target for cancer treatment: the emerging role of IMC-C225 in the treatment of lung and head and neck cancers. Sem Oncol 2002; 29: 27S-36S.
Google Scholar
 
 
17.
Fukuoka M, Yano S, Giaccone G, et al. Final results from a phase II trial of ZD1839 (Iressa) for patients with advanced non-small cell lung cancer (IDEAL 1). Proc Am Soc Clin Oncol 2002; 21: 1188.
Google Scholar
 
 
18.
Kotantoula G, Winterhalder RC. Χημειοπροφύλαξη στον καρκίνο του πνεύμονα. ΠΝΕΥΜΩΝ, 2003, Τεύχος 2 Μάιος-Αύγουστος.
Google Scholar
 
 
19.
Lord RVN, Brabender J, Gandara D, et al. Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Clin Cancer Res, 2002; 8:2286-2291.
Google Scholar
 
 
20.
Rosell R, Danenberg K, Alberola V, et al. Ribonucleotide reductase subunit 1 subunit 1 mRNA expression and survival in gemcitabine/cisplatintreated advanced non-small-cell lung cancer patients. Clin Cancer Res, 2004; 10:1318-1325.
Google Scholar
 
 
21.
Davidson JD, Ma L, Flagella M, et al. An increase in the expression of ribonucleotide reductase subunit 1 large subunit 1 is associated with gemcitabine resistance in non-small cell lung cancer cell lines. Cancer Res, 2004; 64:3761-3766.
Google Scholar
 
 
22.
Bergman A, Eijk P, van Haperen V, et al. In vivo induction of resistance to gemcitabine results in increased expression of ribonucleotide reductase subunit 1 subunit M1 as a major determinant. Cancer Res,2005; 65:9510-9516.
Google Scholar
 
 
23.
Bepler G, Kusmartseva I, Sharma S, et al. RRM1-modulated in vitro and in vivo efficacy of gemcitabine and platinum in non-small cell lung cancer. J Clin Oncol, 2006; 24:4731-4737.
Google Scholar
 
 
24.
Stubbe J. Ribonucleotide reductase subunit 1s in the twenty-first century. Proc Natl Acad Sci USA, 1998; 95:2723-2724.
Google Scholar
 
 
25.
Reed E. ERCC1 and clinical resistance to platinum-based therapy. Clin Cancer Res, 2005; 11:6100-6102.
Google Scholar
 
 
26.
Simon G, Sharma A, Li X, et al. Feasibility and Efficacy of Molecular Analysis-Directed Individualized Therapy in Advanced Non-Small-Cell Lung Cancer. J Clin Oncol, 2007; 25:2741-2746.
Google Scholar
 
 
27.
Laube BL. The expanding role of aerosols in systemic drug delivery, gene therapy, and vaccination. Respir Care. ©Daedalus Enterprises, 2005; 50 (9): 1161-1174.
Google Scholar
 
 
28.
Smaldone GC. Advances in aerosols: adult respiratory disease. J Aerosol Med, 2006; 19: 36-46.
Google Scholar
 
 
29.
Hureaux J, Lagarce F, Gagnadoux F, et al. Lipid nanocapsules: Ready-to-use nanovectors for the aerosol delivery of paclitaxel. Eur J Pharm Biopharm 73, 2009; 06.013:239-246.
Google Scholar
 
 
30.
Gagnadoux F, Hureaux J, Vecellio L, et al. Aerosolized chemotherapy. J Aerosol Med Pulm Drug Deliv, 2008; 21:61-70.
Google Scholar
 
 
31.
Maillet A, Congy-Jolivet N, Les Guellec S, et al. Aerodynamical, immunological and pharmacological properties of the anticancer antibody cetuximab following nebulization. Pharm Res, 2008; 25:1318-26.
Google Scholar
 
 
32.
El-Gendy N, Berkland C. Combination chemotherapeutic dry powder aerosols via controlled nanoparticle agglomeration. Pharm Res 26, July 2009; 1752-1763.
Google Scholar
 
 
33.
Sharma S, White D, Imondi AR, Placke ME, Vail DM, Kris MG. Development of inhalational agents for oncologic use. J Clin Oncol, 2001; 19: 1839-1847.
Google Scholar
 
 
35.
Schevchenko IT, Resnik GE. Inhalation of chemical substances and oxygen in radiotherapy of bronchial cancer. Neoplasma, 1968; 15: 419-426.
Google Scholar
 
 
36.
Camus P, Fanton A, Bonniaud P, Camus C, Foucher P. Interstitial lung disease induced by drugs and radiation. Respiration, 2004; 71: 301-326.
Google Scholar
 
 
37.
Camus P. Interstitial lung disease in patients with non-smallcell lung cancer: causes, mechanisms and management. Br J Cancer 91 (suppl 2): S1-S2, 2004.
Google Scholar
 
 
38.
Wittgen BP, Kunst PW, van der Born K, et al. Phase I study of aerosolized SLIT cisplatin in the treatment of patients with carcinoma of the lung. Clin Cancer Res, 2007; 13: 2414-2421.
Google Scholar
 
 
39.
Dandan Y, Wiedmann TS. Inhalation adjuvant therapy for lung cancer. J Aer Med Pulm Del, 2010; 23(4): 181-187.
Google Scholar
 
 
40.
Labiris NR, Dolovich MB. Pulmonary drug delivery. Part I: physiological factors affecting therapeutic effectiveness of aerosolized medications. Br J Clin Pharmacol, 2003; 56: 588-599.
Google Scholar
 
 
41.
Bhavna ???, Αhmad FJ, Khar RK, Sultana S, Bhatnagar A. Techniques to develop and characterize nanosized formulation for salbutamol sulfate. J Mater Sci Mater Med, 2008; 20:S71–S76.
Google Scholar
 
 
42.
Labiris NR, Dolovich MB. Pulmonary drug delivery. Part II: the role of inhalant delivery devices and drug formulations in therapeutic effectiveness of aerosolized medications. Br J Clin Pharmacol, 2003; 56: 600-612.
Google Scholar
 
 
43.
Wittgen BP, Kunst PW, Perkins WR, Lee JK, Postmus P E. Assessing a system to capture stray aerosol during inhalation of nebulized liposomal cisplatin. J Aerosol Med, 2006; 19: 385-391.
Google Scholar
 
 
44.
Azarmi S, Tao X, Chen H, et al. Formulation and cytotoxicity of doxorubicin nanoparticles carried by dry powder aerosol particles. Int J Pharm. 2006; 319: 155-161.
Google Scholar
 
 
45.
Vlastos F. Θεραπεία του καρκίνου του πνεύμονα: παρόν και μέλλον. Πνεύμων, 2004; 17: 272-288.
Google Scholar
 
 
46.
Otterson GA, Villalona-Calero MA, Sharma S, et al. Phase I study of inhaled doxorubicin for patients with metastatic tumors to the lungs. Clin Cancer Res. 2007; 13(4):1246-52.
Google Scholar
 
 
47.
Haynes A, Shaik MS, Chatterjee A, Singh M. Formulation and evaluation of aerosolized celecoxib for the treatment of lung cancer. Pharm Res, 2005; 22(3):427-39.
Google Scholar
 
 
48.
Fulzele SV, Shaik MS, Chatterjee A, Singh M. Anti-cancer effect of celecoxib and aerosolized docetaxel against human non-small-cell lung cancer cell line, A549. J Pharm Pharmacol, 2006; 58: 327-336.
Google Scholar
 
 
49.
Gagnadoux F, Leblond V, Vecellio L, et al. Gemcitabine aerosol: in vitro antitumor activity and deposition imaging for preclinical safety assessment in baboons. Cancer Chemother Pharmacol, 2006; 58: 237-244.
Google Scholar
 
 
50.
Min R, Li T, Du J, Zhang Y, Guo J, Lu WL. Pulmonary gemcitabine delivery for treating lung cancer: pharmacokinetics and acute lung injury aspects in animals. Can J Physiol Pharmacol 2008; 86: 288-298.
Google Scholar
 
 
51.
Wang Z, Chen HT, Roa W, Finlay WH. Farnesol for aerosol inhalation: nebulization and activity against human lung cancer cells. J Pharm Pharmaceut Sci, 2003; 6: 95-100.
Google Scholar
 
 
52.
Qamar W, Sultana S. Farnesol ameliorates massive inflammation, oxidative stress and lung injury induced by intratracheal instillation of cigarette smoke extract in rats: An initial step in lung chemoprevention. Chem Biol Interac., 2008; 176: 79-87.
Google Scholar
 
 
53.
Tatsumura T, Koyama S, Tsujimoto M, Kitagawa M, Kagamimori S. Further study of nebulisation chemotherapy, a new chemotherapeutic method in the treatment of lung carcinomas: fundamental and clinical. Br J Cancer, 1993; 68: 1146-1149.
Google Scholar
 
 
54.
Lefranc F, Facchini V, Kiss R. Proautophagic drugs: a novel means to combat apoptosis-resistant cancers, with a special emphasis on glioblastomas. Oncologist, 2007; 12: 1305 1403.
Google Scholar
 
 
55.
Choong NW, Mauer AM, Hoffmann PC, et al. Phase II trial of temozolomide and irinotecan as second line treatment for advanced non-small-cell lung cancer. J Thorac Oncol, 2006; 1: 732-733.
Google Scholar
 
 
56.
Tamaskar L, Mekhail T, Dreicer R, et al. Phase I trial of weekly docetaxel and daily temozolomide in patients with metastatic disease. Invest New Drugs, 2008; 26: 553-559.
Google Scholar
 
 
57.
Kouroussis C, Vamvakas L, Vardakis N, et al. Continuous administration of daily low-dose temozolomide in pretreated patients with advanced non-small-cell lung cancer: a phase II study. Oncology, 2009; 76: 112-117.
Google Scholar
 
 
58.
Wauthoz N, Deleuze P, Hecq J, et al. In vivo assessment of temozolomide local delivery for lung cancer inhalation therapy. Eur J Pharmaceut Sci., 2010; 39: 402-411.
Google Scholar
 
 
59.
Anderson PM, Markovic SN, Sloan JA, et al. Aerosol granulocyte macrophage-colony stimulating factor: a low toxicity, lungspecific biological therapy in patients with lung metastases. Clin Cancer Res, 1999; 5: 2316-2323.
Google Scholar
 
 
60.
Gautam A, Waldrep JC, Densmore CL, et al. Growth inhibition of established B16-F10 lung metastases by sequential aerosol delivery of p53 gene and 9-nitrocamptothecin. Gene Therapy, 2002; 9: 353-357.
Google Scholar
 
 
61.
Koshkina NV, Waldrep JC, Knight V. Camptothecins and lung cancer: improved delivery systems by aerosol. Current Cancer Drug Targets, 2003; 3: 251-264.
Google Scholar
 
 
62.
Zou Y, Tornos C, Qiu X, Lia M, Perez-Soler R. p53 aerosol formulation with low toxicity and high efficiency for early lung cancer treatment. Clin Cancer Res, 2007; 13: 4900-4908.
Google Scholar
 
 
Share
Send by email
RELATED ARTICLE
A survival analysis of cutaneous metastases in lung cancer: A 25-year experience
Sphenoid bone metastasis in lung cancer: An unusual finding
Hypertrophic pulmonary osteoarthropathy on bone scintigraphy and somatostatin receptor scintigraphy
Bacillus Calmette-Guerin: Established and emerging roles for an old friend
Lung cancer screening trials: Review of literature
Indexes
 
Keywords index
Topics index
Authors index
eISSN:1791-4914
ISSN:1105-848X
The views and opinions expressed in the published articles are strictly those of the author(s). 21 December 2021.
© 2006-2023 Journal hosting platform by Bentus